Corvus (CRVS) | Financial Analysis & Statements
Corvus Pharmaceuticals Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-12.2M
Net Income
-12.3M
EPS (Diluted)
$-0.15
Balance Sheet Metrics
Total Assets
71.1M
Total Liabilities
9.9M
Shareholders Equity
61.2M
Debt to Equity
0.16
Cash Flow Metrics
Operating Cash Flow
-10.2M
Free Cash Flow
-9.2M
Revenue & Profitability Trend
Corvus Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 33.7M | 19.4M | 16.5M | 24.5M | 29.1M |
| Selling, General & Administrative | 9.3M | 8.2M | 6.9M | 8.1M | 9.5M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 43.0M | 27.5M | 23.4M | 32.6M | 38.6M |
| Operating Income | -43.0M | -27.5M | -23.4M | -32.6M | -38.6M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 2.5M | 1.8M | - | - | - |
| Interest Expense | - | - | - | - | 15.0K |
| Other Non-Operating Income | 25.2M | -36.6M | -5.2M | -9.4M | -4.6M |
| Pre-tax Income | -15.3M | -62.3M | -27.0M | -41.3M | -43.2M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -15.3M | -62.3M | -27.0M | -41.3M | -43.2M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -70.0M | 5.9M | -23.3M | -32.2M | -38.2M |
| EPS (Basic) | - | $-1.02 | $-0.56 | $-0.89 | $-1.03 |
| EPS (Diluted) | - | $-1.02 | $-0.56 | $-0.89 | $-1.03 |
| Basic Shares Outstanding | - | 60985165 | 48025274 | 46553511 | 41854110 |
| Diluted Shares Outstanding | - | 60985165 | 48025274 | 46553511 | 41854110 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Corvus Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 4.6M | 8.7M | 12.6M | 13.2M | 63.5M |
| Short-term Investments | 52.2M | 43.2M | 14.5M | 29.1M | 6.0M |
| Accounts Receivable | 37.0K | 75.0K | 26.0K | 588.0K | 507.0K |
| Inventory | - | - | - | - | - |
| Other Current Assets | 318.0K | 548.0K | 220.0K | 102.0K | 128.0K |
| Total Current Assets | 58.2M | 54.4M | 28.0M | 43.7M | 71.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 3.5M | 3.7M | 3.8M | 4.9M | 5.7M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 855.0K | 632.0K | 89.0K | 129.0K | 236.0K |
| Total Non-Current Assets | 12.9M | 14.5M | 17.6M | 24.6M | 38.1M |
| Total Assets | 71.1M | 68.9M | 45.6M | 68.2M | 109.5M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.5M | 2.6M | 1.5M | 2.0M | 1.6M |
| Short-term Debt | 403.0K | 185.0K | 1.4M | 1.2M | 1.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 238.0K | 29.2M | 245.0K | 158.0K | 121.0K |
| Total Current Liabilities | 9.4M | 35.4M | 6.9M | 10.8M | 9.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 534.0K | 937.0K | 0 | 1.4M | 2.6M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 534.0K | 937.0K | 0 | 1.4M | 2.6M |
| Total Liabilities | 9.9M | 36.3M | 6.9M | 12.1M | 12.3M |
| Equity | |||||
| Common Stock | 7.0K | 7.0K | 5.0K | 5.0K | 5.0K |
| Retained Earnings | -412.3M | -397.0M | -334.7M | -307.7M | -266.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 61.2M | 32.6M | 38.7M | 56.1M | 97.2M |
| Key Metrics | |||||
| Total Debt | 937.0K | 1.1M | 1.4M | 2.6M | 3.6M |
| Working Capital | 48.8M | 19.0M | 21.1M | 32.9M | 61.6M |
Balance Sheet Composition
Corvus Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -15.3M | -62.3M | -27.0M | -41.3M | -43.2M |
| Depreciation & Amortization | 105.0K | 85.0K | 151.0K | 367.0K | 460.0K |
| Stock-Based Compensation | 5.3M | 3.0M | 2.1M | 2.7M | 4.2M |
| Working Capital Changes | -123.0K | 185.0K | -8.0K | 364.0K | -2.4M |
| Operating Cash Flow | -10.0M | -59.0M | -24.7M | -37.9M | -41.0M |
| Investing Activities | |||||
| Capital Expenditures | -174.0K | 5.0K | -34.0K | -247.0K | -5.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -91.8M | -70.1M | -47.0M | -66.2M | -9.4M |
| Investment Sales | 84.1M | 42.6M | 62.6M | 43.2M | 30.9M |
| Investing Cash Flow | -7.8M | -27.5M | 15.5M | -23.3M | 21.6M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 0 | 16.4M | 7.8M | 0 | 60.9M |
| Free Cash Flow | -33.0M | -25.4M | -24.0M | -27.3M | -36.7M |
| Net Change in Cash | -17.8M | -70.1M | -1.4M | -61.2M | 41.5M |
Cash Flow Trend
Corvus Key Financial Ratios
Valuation Ratios
Forward P/E
-20.70
Price to Book
20.93
PEG Ratio
-20.70
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-32.60%
Return on Assets
-38.36%
Financial Health
Current Ratio
6.21
Debt to Equity
1.53
Beta
0.97
Per Share Data
EPS (TTM)
$-0.53
Book Value per Share
$0.82
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CRVS | 1.3B | - | 20.93 | -32.60% | 0.00% | 1.53 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






